Leucid Bio and Lonza Enter Strategic Collaboration to Leverage the Cocoon® Platform for Automated Manufacturing of Personalised CAR T-Cells
-
Leucid will work with Lonza on the Cocoon® Platform for Leucid Bio’s Phase I/II clinical studies with its lead candidate, LEU-011, for the treatment of platinum resistant ovarian cancer
-
Leucid will utilise the Cocoon® Platform through to commercial manufacturing.
London, UK – 2 December 2021 – Leucid Bio (“Leucid” or the “Company”), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, today announces that it has entered a strategic collaboration with Lonza to utilize Lonza’s Cocoon® Platform for the Company’s forthcoming Phase I clinical trial, through to commercial manufacturing.
